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Background: Synthetic biology is a discipline that includes making life forms artificially from chemicals. Here,
a DNA molecule was enzymatically synthesized in vitro from DNA templates made from oligonucleotides
representing the text of the first Tobacco mosaic virus (TMV) sequence elucidated in 1982. No infectious DNA
molecule of that seminal reference sequence exists, so the goal was to synthesize it and then build viral chimeras.
Results: RNA was transcribed from synthetic DNA and encapsidated with capsid protein in vitro to make synthetic
virions. Plants inoculated with the virions did not develop symptoms. When two nucleotide mutations present in
the original sequence, but not present in most other TMV sequences in GenBank, were altered to reflect the
consensus, the derivative synthetic virions produced classic TMV symptoms. Chimeras were then made by
exchanging TMV capsid protein DNA with Tomato mosaic virus (ToMV) and Barley stripe mosaic virus (BSMV) capsid
protein DNA. Virus expressing ToMV capsid protein exhibited altered, ToMV-like symptoms in Nicotiana sylvestris. A
hybrid ORF6 protein unknown to nature, created by substituting the capsid protein genes in the virus, was found
to be a major symptom determinant in Nicotiana benthamiana. Virus expressing BSMV capsid protein did not have
an extended host range to barley, but did produce novel symptoms in N. benthamiana.
Conclusions: This first report of the chemical synthesis and artificial assembly of a plant virus corrects a long-standing
error in the TMV reference genome sequence and reveals that unnatural hybrid virus proteins can alter symptoms
unexpectedly.Background
Tobacco mosaic virus (TMV) has been a model system
in biology for more than 100 years and has led to the
discovery of some of the basic underpinnings of life
[1-4]. It has contributed to fundamental biology and to
the applied sciences, being used to establish genetic
foundations of mutation and plant immunity and to cre-
ate the first transgenic crop plant with an improved agri-
cultural trait [5-7].
Two variant RNA sequences of TMV (GenBank
V01408.1 and V01409.1) were deduced by Goelet et al.
in 1982 [8], making TMV the first plant pathogen and
one of the first life forms to have its genome resolved.
The sequences confirmed that the virus encodes at least
four proteins (Figure 1): the 126 kDa replicase compo-
nent; the 183 kDa replicase component that arises from
translational read-though of the amber termination
codon of the 126 kDa protein gene; a 30 kDa movement
protein (MP) required for TMV RNA translocationCorrespondence: bret.cooper@ars.usda.gov
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unless otherwise stated.between cells; and a 17.5 kDa capsid protein (CP) that
enables long distance spread between leaves and stable
transmission between plants [9]. A fifth, 54 kDa protein,
predicted as the difference between the two replicase
components, has an undefined virological role if any [9],
and a sixth, 4.8 kDa protein, ORF6, encoded by an open
reading frame (ORF) overlapping the MP and CP genes,
influences symptomology [10].
The sequence of TMV variant V01408.1, herein dubbed
the Goelet sequence, became a reference by which all
other plant viruses were compared, and it facilitated the
creation of TMV cDNA from which infectious RNA tran-
scripts could be expressed [11], opening new possibilities
for characterizing the encoded genes and for transiently
expressing foreign genes in plants [12]. Amidst all this
success, however, is the almost forgotten fact that the
Goelet sequence does not represent a single molecule of a
TMV genome. Rather, it is a composite consensus of more
than 400 independent clones of cDNA fragments reverse
transcribed from a population of TMV RNA molecules
exhibiting nucleotide polymorphisms consistent with the
inherent error rate of viral RNA-dependent replication.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Schematic of synthetic TMV. (A) Genome organization. (B) Long-oligonucleotides with 20 or 40 base overlaps. (C) Overlapping
approximately 480 bp molecules made from long-oligonucleotides in (B). (D) Overlapping approximately 1,140 bp molecules made from (C).
(E) Full-length DNA made from molecules from (D).
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Goelet et al. sequenced was a mixture of closely related
strains [13]. Today, the Goelet sequence is the National
Center for Biotechnology Information (NCBI) reference
sequence for TMV (NC_001367.1). In 2009, its accession
was updated to include the ORF6 protein, but to this date
the genomic nucleotide sequence has not been amended.
Furthermore, sequences for more than a hundred TMV
variants or strains have been reported and none has
been merged with NC_001367.1. Consequently, BLAST
alignment of NC_001367.1 to all other full-length TMV
genomic sequences in the partially non-redundant NCBI
Nucleotide collection yields only one hit with perfect iden-
tity: itself. Meanwhile, other TMV variants have been mo-
lecularly cloned and demonstrated to be infectious [11,14],
but there is no known infectious clone for the Goelet se-
quence, and it remains unknown whether the Goelet se-
quence represents an infectious viral molecule.
The molecular biology techniques that first enabled
the cDNA cloning of TMV 32 years ago have matured
to the point where it is now possible to synthesize DNA
molecules from basic chemicals in the absence of pre-
cursor biological template molecules such as RNA. This
advance is part of the domain called synthetic biology, a
discipline that can be used to verify the veracity of
genome sequences, perform archeology, and assemble
genomes de novo [15,16]. Poliovirus was the first virus to
have its genome chemically synthesized based on an
alphabetic text blueprint of its nucleotide sequence, a
feat later performed for other animal and bacterial
viruses [16-25]. The complete chemical synthesis of a
plant virus genome, however, has not yet been reported.
To achieve this mark, DNA was enzymatically synthe-
sized from overlapping oligonucleotides based on the
Goelet alphabetic rendering of TMV and was thentranscribed into RNA that was artificially packaged into
virions with purified TMV CP in vitro. The man-made
virus particles encoding the Goelet sequence, a mutant
thereof, and two viral chimeras were tested in plants.
Results and discussion
Goelet sequence DNA synthesis from modular clones
Thirty sets of long-oligonucleotides with complemen-
tary, overlapping ends were chemically synthesized for
construction of a linear DNA molecule encoding the
Goelet TMV sequence (Figure 1). The DNA molecule
also was designed to encode the T7 RNA polymerase
promoter for RNA transcription in vitro and to have
flanking sequences for PCR amplification. Sets of long-
oligonucleotides were assembled to create 15, approxi-
mately 480 bp DNA modules (Figure 1) that were cloned
in plasmids and sequenced. Only six clones for each
construct needed to be screened to find at least one with
a perfect module sequence, except in one case where it
required the screening of 13 clones. The frequency of
correct to incorrect modules and the error rate were
similar to those previously reported for modules used to
synthesize the mouse mitochondrial genome [26].
DNA was amplified from the modules, and the full-
length DNA molecule of the Goelet sequence, called
1-30, was enzymatically synthesized from overlapping in-
termediates using 3 PCR steps for a total of 60 cycles
(Figure 1) and was accomplished in 2 to 3 days by the
author (fragment size selection by gel purification was
the most time consuming step). This time estimate is
consistent with the 5-day estimate reported for the PCR
synthesis and enzymatic assembly of the mouse mito-
chondrial genome, which is roughly double the size [26].
7-Methyl guanosine capped-RNA was transcribed
in vitro from gel purified PCR product of 1-30 and was
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(tobacco), but no hypersensitive local lesions, the classic
marks of infection, appeared. By contrast, the same
amounts of RNA from DNA made by PCR amplification
of the control plasmid pFL-TMV-NA, a known infec-
tious TMV cDNA clone expressed by a T7 promoter
[14,27], did produce local lesions on NN tobacco. FL-
TMV-NA RNA, however, only produced 4 to 10 local
lesions per leaf, which suggested low inoculation poten-
tial. Because TMV RNA is susceptible to nuclease deg-
radation and is less infectious than packaged virus [28],
the transcribed RNA was encapsidated in vitro with CP
isolated from purified FL-TMV-NA virions. On the basis
of the number of local lesions, encapsidation improved
the infectivity of control FL-TMV-NA RNA by three to
five times (purified CP preparations by themselves did
not produce symptoms). The CP then was used to en-
capsidate 1-30 RNA, but the preparation still did not
produce local lesions on NN tobacco or mosaic symp-
toms on Xanthi nn tobacco (SX), the classic systemic-
symptom host. The experiment was repeated, but again
1-30 virus was not infectious.
Uncommon polymorphisms in the Goelet sequence
The lack of symptoms implied that 1-30 DNA may not
be error-free. To examine its integrity, 1-30 DNA was li-
gated into a plasmid and four clones were sequenced.
Three clones perfectly matched the Goelet sequence
whereas the fourth contained a single, silent mutation.
Encapsidated RNA transcripts prepared from one plas-
mid with a perfect Goelet sequence produced no symp-
toms on NN and SX tobacco. Therefore, the integrity of
1-30 DNA was not to blame. Instead, the Goelet se-
quence itself was suspicious.
The DNA sequence of control pFL-TMV-NA was
compared to the text of the Goelet sequence and three
major differences were found. pFL-TMV-NA contains
substitutions that add restriction endonuclease sites
NdeI before the MP start codon and AflII before the MP
stop codon. These substitutions have no detrimental
effects on viral pathogenicity. pFL-TMV-NA also con-
tains a G to A substitution at nucleotide position 832
(with respect to the Goelet sequence), which leads to
an E instead of G at amino acid position 255 in the
replicase (Figure 2). This is a unique polymorphism thatFigure 2 Sequence polymorphisms between the Goelet sequence and
632 and 825 to 833. The corresponding translated amino acids (a.a) are sho
the replicase.also serves as a distinguishing marker for FL-TMV-NA.
The other deviation is an A deletion at nucleotide pos-
ition 624 followed by an A insertion five bases later that
preserves the integrity of the reading frame, but changes
two consecutive amino acids in the replicase at positions
186 and 187 from MR to CE (Figure 2). This last devi-
ation was noticed as early as 1990, but no effect was at-
tributed to it [29].
To evaluate the prevalence of the MR polymorphism
among TMV isolates, the Goelet amino acid sequence
from amino acids 166 to 207 was compared to the NCBI
non-redundant protein sequence database by BLASTP.
Identical matches were made to the MR amino acids in
the first seven reported TMV replicase records, three of
which referenced the Goelet sequence. The CE amino
acids, however, appeared in 58 of the following TMV
replicase records. The next match in the BLASTP report
to deviate from CE was that for Tomato mosaic virus
(ToMV), a closely related tobamovirus, which encoded
CR instead. The C at amino acid position 186 is also
conserved in other tobamoviruses such as Bell pepper
mottle virus, Tobacco mild green mosaic virus, Sunn-
hemp mosaic virus, and Odontoglossum ringspot virus.
Hence, the lack of prevalence of the MR polymorphism
among TMV isolates and related tobamoviruses implies
that the Goelet DNA sequence for nucleotides 624 to
629 may be an artifact of reverse transcription, DNA se-
quencing, or human error.
An infectious, synthetic TMV
The MR amino acid polymorphism is suspicious because
it is uncommon among TMV replicases and because it
arises in the Goelet sequence from an insertion and
deletion event rather than the more prevalent single
nucleotide substitution. To see if the MR sequence ex-
plained why RNA from 1-30 was not infectious, new clones
for module 3-4 were made from long-oligonucleotides en-
coding CE, and linear DNA for 1-34CE-30 was amplified
and transcribed. This time, synthetic virions of 1-34CE-30
produced classic mosaic symptoms on SX and local lesions
on NN tobacco (Figure 3A,C,D). Viral cDNAs amplified
from local lesions encoded CE amino acids, but they did
not contain the G to A polymorphism at nucleotide
position 832. Therefore, the virus causing the symptoms
was derived from the synthetic 1-34CE-30 DNA moleculeFL-TMV-NA. Alignment of DNA nucleotides from positions 615 to
wn, and the differences are in boldface type. This region is in
Figure 3 Encapsidation and infectivity of synthetic 1-34CE-30 and 1-34CE-ToMV CP-30. (A) 1-34CE-30 RNA encapsidated in vitro with
FL-TMV-NA CP (stained with uranyl acetate and imaged by transmission electron microscopy; distance between first and last black ticks in white
bar = 200 nm). (B) FL-TMV-NA CP disks prior to the addition of 1-34CE-30 RNA (stained with uranyl acetate and imaged by transmission electron
microscopy; distance between first and last black ticks in white bar = 100 nm). (C) Mosaic symptoms on N. tabacum cv. Xanthi SX plant inoculated
with encapsidated 1-34CE-30 (4 weeks after inoculation). (D) N. tabacum cv. Xanthi NN local lesions from 1-34CE-30 are to the left of the midrib
and local lesions from 1-34CE-ToMV CP-30 are to the right. (E) 1-34CE-ToMV CP-30 virion from Xanthi SX (stained with uranyl acetate and imaged by
transmission electron microscopy; distance between first and last black ticks in white bar = 200 nm). (F) N. sylvestris infected with 1-34CE-ToMV CP-30.
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preparation.
Capsid protein complementation
It has been known since the 1950s that the CPs from
tobamoviruses like Holmes ribgrass virus can transen-
capsidate homologous TMV RNA in vitro [30]. At the
time of discovery, the results inspired the question
whether CP genes were interchangeable among tobamo-
viruses, but it took the advent of molecular biological
techniques to test the idea. In an early report of plant
viral genome recombination, an infectious cDNA of
ToMV was engineered to express the CP gene of TMV
[31]. The feat, however, required the generation of separ-
ate cDNAs for ToMV and TMV, restriction endonucle-
ase mapping, subcloning, and site-directed mutagenesis
with phage to create a chimera that had additional
sequence alterations in the MP gene and the CP
promoter [31]. Here, using more precise synthetic
techniques, the interchangeability of CPs was revisited.
The ORF sequences for the 1-34CE-30 CP gene and the
ToMV CP gene were swapped within a text file, and 10
corresponding long-oligonucleotides were synthesized.
Full-length DNA was amplified from perfect plasmid
clones for two new modules, and RNA was transcribed
and encapsidated in vitro. The chimera synthetic virus1-34CE-ToMV CP-30 produced local lesions on Xanthi
NN within 5 days (Figure 3D) and mosaic symptoms on
Xanthi SX within 7 days. The rapid systemic infection in
SX indicated that the ToMV CP complemented long-
distance transport function in lieu of the TMV CP [32].
Mass spectrometry confirmed the presence of ToMV CP
distinguishing peptides in the NN local lesions, and this
evidence also verified that the symptoms were not a re-
sult of contaminating FL-TMV-NA from the CP prepar-
ation (Table 1). Transmission electron microscopy
confirmed ToMV CP encapsidation of the chimera virus
progeny in Xanthi SX (Figure 3E).
TMV and ToMV can be distinguished by the symp-
toms they produce on N. sylvestris that has the N’ gene,
which confers hypersensitive resistance to ToMV but
not to wild-type TMV. N’ encodes a protein with a
coiled-coil domain, nucleotide binding site, and a
leucine-rich repeat like many other plant disease
resistance genes [33]. The elicitor of N’ was mapped
indirectly to the ToMV CP gene by Saito et al. [31], who
replaced the ToMV CP with an homologous TMV CP
gene restriction fragment in an infectious ToMV clone
and observed the loss of N’ elicitation. Around the same
time, Dawson and colleagues [34,35] showed that some
RNA mutations in the TMV CP gene were sufficient for
eliciting N’, and their data also indirectly implicated the
Table 1 Virus peptides identified from plants by tandem mass spectrometry


















RVDDATVAIR 2 1 50 3.20E-
03
558.3115 1114.6095 2+ ToMV CP
IIEVENQQSPTTAETLDATR 2 0 122 3.50E-
11





RVDDATVAIR 2 1 50 2.40E-
03
558.3115 1114.6095 2+ ToMV CP
IIEVENQQSPTTAETLDATR 2 0 128 2.10E-
11






RVDDATVAIR 3 1 58 1.20E-
03
558.3113 1114.6095 2+ ToMV CP
SAINNLVNELVR 6 0 81 4.30E-
06
671.3783 1340.7412 2+ ToMV CP
IIEVENQQSPTTAETLDATR 1 0 105 2.20E-
09
1108.5542 2215.0968 2+ ToMV CP
TTVQQQFSEVWKPFPQSTVR 1 0 89 1.70E-
08





SQVAEYLAALDR 3 0 104 4.90E-
08
668.3484 1334.6830 2+ BSMV CP
GQIGLPNYLPAPK 1 0 49 4.50E-
04
684.3877 1366.7609 2+ BSMV CP
ATTNPSPPAQAPSENLTLR 1 0 109 2.00E-
09
983.0071 1963.9963 2+ BSMV CP
*Mascot was used for peptide-spectrum matching.
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variants of TMV CP, and not TMV CP gene RNA, in-
deed elicited N’ [36,37], but the same has never been
shown for ToMV CP, although this is a technicality since
the results for mutant TMV CP clearly implicate ToMV
CP as well. Nevertheless, it was necessary to examine
synthetic chimera 1-34CE-ToMV CP-30 virus on N. syl-
vestris to confirm the hypothesis that it would exhibit a
ToMV-like phenotype. So leaf extract from 1-34CE-
ToMV CP-30 virus-infected Xanthi SX was inoculated
to N. sylvestris. Local lesions appeared within 3 days
(Figure 3F). By comparison, 1-34CE-30 virus produced
systemic symptoms, but no local lesions on N. sylvestris.
Thus, this experiment directly demonstrates that the N’
elicitor is included within the coding region of the
ToMV CP gene.Figure 4 Effects of ORF6 on symptomology. Symptoms on N. benthamiAdditional experiments, the descriptions of which will
follow, were required to validate the ToMV CP proper
as the elicitor, but there were unintended consequences
with synthesizing 1-34CE-ToMV CP-30 DNA that first
needed to be reconciled. TMV and ToMV also can be
distinguished by the symptoms they produce on Nicoti-
ana benthamiana. For example, 1-34CE-30 virus caused
severe epinasty, chlorosis, curling, and lethal systemic
leaf and stem necrosis (Figure 4). Symptoms by ToMV
were less severe by comparison, but still detrimental
(Figure 4). Symptoms produced by chimera virus 1-34CE-
ToMV CP-30 on N. benthamiana were more similar to
those produced by ToMV (Figure 4). DNA sequencing of
reverse transcription-PCR (RT-PCR) products from in-
fected N. benthamiana revealed no sequence mutations in
1-34CE-ToMV CP-30. Therefore, these results appearedana 14 days after inoculation with the respective viruses.
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in N. benthamiana, reminiscent of the way they did in
N. sylvestris. Confounding a final conclusion, however, was
the ORF6 gene, which overlaps the TMV MP and CP
genes. Since TMV ORF6 has been implicated in sympto-
mology [10], it was possible that the slightly milder symp-
toms of ToMV were attributed to ToMV ORF6, which is
shorter than and divergent to TMV ORF6, especially in
the carboxyl terminus region, which is encoded within the
overlapping CP gene (Figure 5A). Similarly, the ToMV-
like symptoms of 1-34CE-ToMV CP-30 virus may have
been attributed to the hybrid ORF6 arising from replacing
the coding region of the TMV CP gene with the coding re-
gion of the ToMV CP gene; the final 16 of 34 amino acids
of the hybrid ORF6 are derived from ToMV as well. To
determine the role of hybrid ORF6 in symptomology,
the codons for the first two methionines of ORF6
were mutated to eliminate potential translational starts
(the mutations were silent to the MP). Symptoms for the
new virus, 1-34CE-ToMVnoorf6-30, were even milder on
N. benthamiana compared to the other viruses with func-
tional ORF6 genes (Figure 4). DNA sequencing of RT-Figure 5 Needleman-Wunsch amino acid alignment for ORF6 and CP
CP gene start codon is shown by the arrow. (B) CP. Dots indicate identicalPCR products confirmed that the ORF6 translational start
mutations were retained; no mutations were found in the
rest of the viral genome. Mass spectrometry verified the
production of ToMV CP (Table 1). Thus, while it is not
ruled out that ToMV CP is not a symptom determinant in
N. benthamiana, it is clear that ORF6 is. The results imply
that the carboxyl end of ORF6 that overlaps the TMV CP
gene influences symptoms the most. The results also reveal
that unnatural hybrid proteins created by viral genome
synthesis can unpredictably alter disease symptoms.
Because hybrid ORF6 influences symptoms in N.
benthamiana and is partly encoded by the ToMV CP
gene to which N’ gene elicitation is mapped, it was ne-
cessary to rule out whether hybrid ORF6 contributes to
elicitation. Thus, 1-34CE-ToMVnoorf6-30 virus, isolated
from N. benthamiana, was inoculated to N. sylvestris.
Local lesions appeared 3 days later. Hence, N’ elicitation
is attributed to the part of the gene that encodes the
ToMV CP, not the part that encodes ORF6. Like the
type strain of ToMV, 1-34CE-ToMV CP-30 virus does
not have a mutation in its ToMV CP gene RNA. Thus,
RNA structural alterations encoded by the ToMV CPof the respective viruses. (A) ORF6. The nucleotide position for the
amino acids; plus signs indicate similar amino acids.
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is the elicitor of N’.
Finally, CP complementation was explored between
TMV and the heterologous Barley stripe mosaic virus
(BSMV), a rod-shaped virus that exhibits CP sequence
divergence to TMV and ToMV (Figure 5B). Although
barley, Hordeum vulgare cv. Black Hulless, is a natural
host for BSMV but not TMV, it was demonstrated that
in the presence of a mixed infection with BSMV, TMV
RNA transencapsidated by BSMV CP could be recovered
from upper leaves of barley [38,39]. It can be hypothe-
sized from these results that the BSMV CP aids the sys-
temic spread of TMV in barley, but the role for BSMV
CP in extending the host range of TMV has remained
unknown since the 1970s. To examine this, oligonucleo-
tides were designed from the BSMV CP gene text and
used to replace the TMV CP gene to create 1-34CE-
BSMV CP-30 DNA. This design also resulted in a trun-
cated TMV ORF6 with just seven amino acids provided
by the overlapping BSMV CP gene sequence (Figure 5A).
The derivative chimera virus did not produce any symp-
toms on inoculated Xanthi SX leaves, but it did produce
TMV-like localized necrosis on the inoculated leaves
of N. benthamiana 3 weeks after infection. The virus
moved systemically 1 week later and produced unique
mosaic symptoms without the systemic necrosis and
stunting previously seen with 1-34CE-30 or 1-34CE-
ToMV CP-30 viruses (Figures 4 and 6A). DNA sequen-
cing of viral genome RT-PCR products from infected
N. benthamiana revealed a single mutation, T to A at
position 6,415 in the 3′ untranslated terminal region.
This mutation is uncommon among TMV isolates; it
was not present in the template DNA modules and may
have arisen from DNA or RNA polymerase error, or it
may have evolved in the plant. BSMV CP distinguishing
peptides were identified from the infected N. benthami-
ana by mass spectrometry (Table 1), and transmission
electron microscopy confirmed BSMV CP encapsidation
of the chimera virus (Figure 6B). Together these resultsFigure 6 Synthetic 1-34CE-BSMV CP-30. (A) Mosaic symptoms on
N. benthamiana. (B) Virion from N. benthamiana (stained with uranyl
acetate and imaged by transmission electron microscopy; distance
between first and last black ticks in white bar = 100 nm).imply that the unique symptoms were a result of the
BSMV CP or the hybrid ORF6, although the point muta-
tion cannot be discounted. Infected N. benthamiana
leaves were used as inocula for Xanthi NN and barley.
Local lesions appeared on Xanthi NN within 4 days, but
after several attempts at inoculating and then growing
barley for 3 weeks at 30°C as described for mixed infec-
tions [38], the viral chimera could not be identified
by RT-PCR from upper leaves. So, even though this
chimera does not explain the spread of TMV in barley
in a mixed infection with BSMV [38,39], it does, like the
previous TMV/ToMV chimera, reveal that synthetic
chimera viruses can produce unexpected and unusual
symptoms.
Conclusions
The number of organisms with sequenced genomes has
grown in recent years, yet the veracity of nearly all of
these genome sequences remains hypothetical. Synthetic
biology provides a means for proving whether a se-
quence is a true blueprint for life. To date, only a few
viral sequences and a lone prokaryotic genomic se-
quence have been authenticated [17,40]. This cannot be
said, however, for the original TMV sequence [8]. RNA
transcribed from an enzymatically synthesized DNA
template of the Goelet sequence is not infectious. The
cause appears to be related to insertion/deletion poly-
morphisms not in most other TMV sequences. The
polymorphisms lead to the translation of MR amino
acids instead of CE amino acids at positions 186 and 187
of the 126 kDa and 183 kDa replicase components. It is
possible that MR disrupts the replicase methyltransfer-
ase domain critical for interactions with host proteins or
with the 3′ end of TMV RNA [41-44]. The origins of
the deleterious polymorphisms are not known with cer-
tainty, but it is unlikely that they were native to the
TMV studied by Goelet et al. Thus, this report identifies
a longstanding error in a model, reference sequence, but
also proves that a corrected sequence sustains biological
replication (Figure 3C).
Synthetic biology also can be used to identify the func-
tions of genes. The TMV CP gene was exchanged with
the homologous ToMV CP gene to test complementa-
tion. The chimera virus, 1-34CE-ToMV CP-30, moved
systemically through tobacco, and this verified that
ToMV CP can complement the long-distance transport
function of the TMV CP. Furthermore, the chimera, as
expected, produced ToMV-like local lesions rather than
TMV-like systemic mosaic in N. sylvestris (Figure 3F).
The local lesions, controlled by N’, were elicited by
ToMV CP translated from the inserted gene. This inser-
tion, however, also created a hybrid ORF6 gene overlap-
ping the reading frames of the TMV MP gene and the
exchanged ToMV CP gene (Figure 5A). Unexpectedly,
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severity in another plant, N. benthamiana (Figure 4).
While ToMV CP was sufficient for complementing
systemic spread of chimera virus 1-34CE-ToMV CP-30
in three tobacco hosts, BSMV CP was not sufficient for
enabling the systemic spread of chimera virus 1-34CE-
BSMV CP-30 in barley, a non-host for TMV. Thus,
transencapsidation of TMV by BSMV in barley may only
be a consequence of mixed infection and may not ex-
plain spread in the non-host [39]. It is possible that the
BSMV triple-gene-block, which is analogous in function
to the TMV MP, is needed to support the spread of
TMV in barley [45]. Nevertheless, 1-34CE-BSMV CP-30
virus did spread systemically through N. benthamiana
and produced unique mosaic symptoms instead of
TMV-like systemic necrosis (Figure 6A). It is possible
that the novel symptoms were a result of replacing the
TMV CP with the BSMV CP, which also led to a potential
truncated TMV/BSMV hybrid ORF6 protein (Figure 5A).
Thus, it should be clear that the inconspicuous ORF6 and
its unnatural derivatives created by synthetic recombination
can have pathological consequences. Embedded in the
TMV genome are several other small ORFs that have not
been examined for pathological importance, possibly be-
cause of the past difficulty of using traditional molecular
biology techniques to decouple these potential ORFs from
the critical replicase, MP, and CP genes in which they are
embedded. It should be feasible to use synthetic biology to
restructure the ORFs in the TMV genome and separate the
genetic responsibilities of these potential, undiscovered
genes much in the same way the bacteriophage genome
was refactored [20,21].
Synthetic genomes have been previously created for a
few animal and bacterial viruses [16-25]. These genomes
were usually maintained in DNA plasmids or were circu-
larized for infectivity. By contrast, with the exception of
the non-infectious Goelet replica, the synthetic DNA
templates of the infectious plant viruses studied here
were not maintained in bacterial plasmids. As linear
DNA molecule templates, they are benign and incapable
of natural biological replication either in bacteria or
plants. Because TMV is an RNA virus, synthetic RNA
needed to be transcribed in vitro from DNA. To im-
prove infectivity, virions were constituted in vitro by
combining the synthetic RNA with purified TMV CP;
virion formation was confirmed by electron microscopy
(Figure 3A). These particles may be considered to be
the first synthetic virions because they were assembled
in vitro from purified CP and synthetic RNA transcribed
from synthetic DNA in the absence of potential host fac-
tors [19], although there is opportunity yet to supersede
this achievement by formulating fully synthetic virus
components entirely by macromolecular chemistry. That
detail is trivial, however, compared to the more poignantobservation that these man-made plant viruses with sim-
ple mutations and recombined genomes altered symp-
toms in both expected and unexpected ways, portending
the ramifications of the artificial manufacture of inher-
ently stable infectious entities [25]. Consequently, all
plants and experimental materials that came into contact




The basic nucleotide blueprint was the M13 (-20) primer
sequence as an anchor, the T7 minimal promoter se-
quence immediately followed by the DNA conversion of
the Goelet sequence (GenBank Refseq NC_001367.1;
6395 nucleotides), and a terminal KpnI cleavage se-
quence (total length 6,443 nucleotides; Figure 1). KpnI
cleavage of a plasmid encoding TMV adds five nucleotides
to the end of the virus but does not inhibit TMV RNA in-
fectivity [14]. The KpnI cleavage site sequence was added
for PCR amplification in light of the predicted high degree
of secondary structure in the TMV 3′ end [46]. The CP
DNA sequences for ToMV (GenBank X02144.1) and
BSMV (GenBank U35772.1) were also used.
Oligonucleotide design
Long-oligonucleotides with complementary overlapping
ends were designed from the blueprint to allow con-
struction of DNA by overlapping PCR [47]. A modular
strategy was adopted such that larger DNA molecules
could be built from smaller units (Figure 1). Sets of 4
or 6 long-oligonucleotides were designed to overlap each
other by 40 bases, with the exception of sets 15 and 16,
which overlapped each other by 220 bases, and the first and
last, which did not overlap with each other, thereby main-
taining the linearity of the molecule (Additional file 1).
Long-oligonucleotides were designed regardless of their po-
tential secondary structures. Amplification oligonucleotides
(Ampoligos), the lengths of which were optimized for 55 to
65°C annealing temperatures for PCR, anchored the ends
of each module. Oligonucleotides were procured from Invi-
trogen (Carlsbad, CA, USA), ordered on a 25 nmol scale,
and diluted to 100 μM in water.
DNA construction
Each long-oligonucleotide (0.5 μl) of two consecutive sets
of long-oligonucleotides (Figure 1) was annealed in 16 to
18 μl TE buffer by heating to 95°C for 1 minute and cool-
ing to 30°C at 0.1°C/s. Annealed long-oligonucleotides
(0.5 μl) were reacted with 4.5 μl synthesis reaction mix
(1 μl 5× isothermal reaction buffer [48], 0.1 unit Phusion
DNA polymerase (Thermo Scientific, Waltham, MA,
USA), 16 units Taq DNA ligase (New England Biolabs,
Ipswich, MA, USA), and water) at 50°C for 1 h. The
Cooper Genome Biology 2014, 15:R67 Page 9 of 10
http://genomebiology.com/2014/15/5/R67assembly (0.5 μl) was amplified by PCR for 20 cycles using
amplification oligonucleotides and Phusion Hot Start II
DNA polymerase (Thermo Fisher Scientific). DNA was
separated by agarose-gel electrophoresis. DNA fragments
were purified using UltraClean 15 (MO BIO Laboratories,
Carlsbad, CA, USA).
DNA cloning
DNA molecules approximately 480 bp long made from 2
sets of overlapping long-oligonucleotides and amplified
in 20 PCR cycles were inserted into pCR-Blunt II-TOPO
(Invitrogen) and propagated and selected in Escherichia
coli. Cloned plasmids were sequenced by Genewiz
(Germantown, MD, USA) using the Sanger method. For
some 1-30 full-length molecules, DNA was amplified
with oligonucleotides with XhoI and KpnI restriction
endonuclease sites, digested, and ligated into pUC18
digested with SalI and KpnI, and the plasmids were
transformed into Stbl2 E. coli (Invitrogen).
RNA transcription
7-Methyl guanosine capped-RNA was produced from
250 to 1,000 ng DNA using the mMESSAGE mMA-
CHINE T7 transcription kit (Ambion/Life Technologies,
Carlsbad, CA, USA). Reactions were supplemented with
0.5 μl GTP. A PCR product (using Ampoligos 1 F and
30 R) of plasmid pFL-TMV-NA, a derivative of pU3/12
with unique NdeI and AflII restriction sites near the start
and stop codon of the MP gene [14,27], was evaluated as
a control.
Viral RNA encapsidation
Virions of FL-TMV-NA and 1-34CE-ToMV CP-30 were
purified from infected Xanthi SX, and virions of 1-34CE-
BSMV CP-30 were purified from infected N. benthamiana
[49]. FL-TMV-NA CP was purified from virions using the
glacial acetic acid degradation method [50]. RNA (2 μg)
was encapsidated in a reaction with 100 μg of purified
FL-TMV-NA CP [30].
RT-PCR
RNA was extracted from 1 cm2 leaf disks from plants
showing viral symptoms using the RNeasy Plant Mini
Kit (Qiagen, Germantown, MD, USA). RNA (10 μl) was
annealed to Ampoligo 30 R and reverse transcribed
using SuperScript III (Life Technologies, Carlsbad, CA,
USA). cDNAs of viral genomes were amplified using
Ampoligos and were sequenced by Genewiz using the
Sanger method.
Mass spectrometry
Protein was extracted from 1 cm2 leaf disks from plants
showing viral symptoms by grinding in liquid nitrogen
and precipitating in acetone/10% trichloracetic acid/0.07% beta-mercaptoethanol. Extracts were centrifuged
at 21,000 × g for 15 minutes and washed two times in
acetone. The residue was dried by vacuum centrifugation
and resuspended in 100 μl 100 mM Tris base pH 8.5
and 8 M urea. Concentrations of soluble protein were
determined by bicinchoninic acid assay (Pierce/Thermo
Fisher Scientific, Carlsbad, CA, USA). Soluble protein
(300 μg) was reduced, derivatized, digested in trypsin
and analyzed by reverse phase-tandem mass spectrom-
etry as previously detailed [51]. Tandem mass spectra
were analyzed with Mascot 2.4.0 against virus protein re-
cords in the NCBI NR protein sequence database. Pep-
tides with P-values less than 0.05 were accepted. Spectra
matching viral peptides were confirmed not to have
equivalent or better matches to plant protein records in
NR. Tandem mass spectrometry data (RAW files) are ar-
chived at [52].
Additional file
Additional file 1: Table S1. Oligonucleotide sequences used for
constructing synthetic viral genomes and the sequences of the
assembled DNA constructs of the synthetic viral genomes.
Abbreviations
bp: base pair; BSMV: Barley stripe mosaic virus; CP: capsid protein;
MP: movement protein; NCBI: National Center for Biotechnology Information;
ORF: open reading frame; PCR: polymerase chain reaction; RT-PCR: reverse
transcription-PCR; SX: Xanthi nn tobacco; TMV: Tobacco mosaic virus;
ToMV: Tomato mosaic virus.
Competing interests
The author declares that he has no competing interests.
Authors’ contributions
The author was responsible for experimental conception, design, execution,
analysis and interpretation of data; drafting and revising the article; and final
approval of the version to be published.
Acknowledgements
The research was funded entirely by the USDA-ARS. I thank Kimberly
Campbell in my lab for growing plants, Wesley Garrett in the Animal
Biosciences and Biotechnology Laboratory for mass spectrometry, and
Charles Murphy in the Soybean Genomics and Improvement Laboratory
for transmission electron microscopy. This work is dedicated to my TMV
forefathers, CM Deom, RN Beachy and JA Dodds.
Received: 23 January 2014 Accepted: 30 April 2014
Published: 30 April 2014
References
1. Beijerinck MW: Over een contagium vivum fluidum als oorzaak van de
vlekziekte der tabaksbladen. Ver sl Gewone Vergad Wis- Natuurkd Afd, K
Akad Wet Amsterdam 1898, 7:229–235.
2. Fraenkel-Conrat H: The role of the nucleic acid in the reconstitution of
active tobacco mosaic virus. J Am Chem Soc 1956, 778:882–883.
3. Gierer A, Schramm G: Infectivity of ribonucleic acid from tobacco mosaic
virus. Nature 1956, 177:702–703.
4. Iwanowski D: Ueber die Mosaikkrankheit der Tabakspflanze. Bull Acad Imp
Sci St-Petersbourg [NW] 1892, 3:65–70.
5. Abel PP, Nelson RS, De B, Hoffmann N, Rogers SG, Fraley RT, Beachy RN:
Delay of disease development in transgenic plants that express the
tobacco mosaic virus coat protein gene. Science 1986, 232:738–743.
Cooper Genome Biology 2014, 15:R67 Page 10 of 10
http://genomebiology.com/2014/15/5/R676. Holmes FO: Inheritance of resistance to tobacco-mosaic disease in
tobacco. Phytopathology 1938, 28:553–561.
7. McKinney HH: Evidence of virus mutation in the common mosaic of
tobacco. J Agric Res 1935, 51:951–981.
8. Goelet P, Lomonossoff GP, Butler PJ, Akam ME, Gait MJ, Karn J: Nucleotide sequence
of tobacco mosaic virus RNA. Proc Natl Acad Sci U S A 1982, 79:5818–5822.
9. Zaitlin M: Elucidation of the genome organization of tobacco mosaic
virus. Philos Trans R Soc Lond B Biol Sci 1999, 354:587–591.
10. Canto T, MacFarlane SA, Palukaitis P: ORF6 of Tobacco mosaic virus is a
determinant of viral pathogenicity in Nicotiana benthamiana. J Gen Virol
2004, 85:3123–3133.
11. Dawson WO, Beck DL, Knorr DA, Grantham GL: cDNA cloning of the
complete genome of tobacco mosaic virus and production of infectious
transcripts. Proc Natl Acad Sci U S A 1986, 83:1832–1836.
12. Dawson WO: A personal history of virus-based vector construction.
Curr Top Microbiol Immunol 2011, 375:1–18.
13. Meshi T, Ishikawa M, Takamatsu N, Ohno T, Okada Y: The 5′-terminal
sequence of TMV RNA. Question on the polymorphism found in vulgare
strain. FEBS Lett 1983, 162:282–285.
14. Holt CA, Beachy RN: In vivo complementation of infectious transcripts
from mutant tobacco mosaic virus cDNAs in transgenic plants.
Virology 1991, 181:109–117.
15. Gibson DG, Benders GA, Andrews-Pfannkoch C, Denisova EA, Baden-Tillson H,
Zaveri J, Stockwell TB, Brownley A, Thomas DW, Algire MA, Merryman C, Young
L, Noskov VN, Glass JI, Venter JC, Hutchison CA 3rd, Smith HO, Merryman C,
Young L, Noskov VN, Glass JI, Venter JC, Hutchison CA, Smith HO: Complete
chemical synthesis, assembly, and cloning of a Mycoplasma genitalium
genome. Science 2008, 319:1215–1220.
16. Tumpey TM, Basler CF, Aguilar PV, Zeng H, Solorzano A, Swayne DE, Cox NJ,
Katz JM, Taubenberger JK, Palese P, Garcia-Sastre A: Characterization of the
reconstructed, Spanish influenza pandemic virus. Science 1918, 2005:77–80.
17. Wimmer E, Mueller S, Tumpey TM, Taubenberger JK: Synthetic viruses: a
new opportunity to understand and prevent viral disease. Nat Biotechnol
2009, 27:1163–1172.
18. Becker MM, Graham RL, Donaldson EF, Rockx B, Sims AC, Sheahan T, Pickles
RJ, Corti D, Johnston RE, Baric RS, Denison MR: Synthetic recombinant bat
SARS-like coronavirus is infectious in cultured cells and in mice. Proc Natl
Acad Sci U S A 2008, 105:19944–19949.
19. Cello J, Paul AV, Wimmer E: Chemical synthesis of poliovirus cDNA: generation of
infectious virus in the absence of natural template. Science 2002, 297:1016–1018.
20. Chan LY, Kosuri S, Endy D: Refactoring bacteriophage T7. Mol Syst Biol
2005, 1:2005 0018.
21. Jaschke PR, Lieberman EK, Rodriguez J, Sierra A, Endy D: A fully
decompressed synthetic bacteriophage oX174 genome assembled and
archived in yeast. Virology 2012, 434:278–284.
22. Smith HO, Hutchison CA 3rd, Pfannkoch C, Venter JC: Generating a synthetic
genome by whole genome assembly: phiX174 bacteriophage from
synthetic oligonucleotides. Proc Natl Acad Sci U S A 2003, 100:15440–15445.
23. Takehisa J, Kraus MH, Decker JM, Li Y, Keele BF, Bibollet-Ruche F, Zammit KP,
Weng Z, Santiago ML, Kamenya S, Wilson ML, Pusey AE, Bailes E, Sharp PM,
Shaw GM, Hahn BH: Generation of infectious molecular clones of simian
immunodeficiency virus from fecal consensus sequences of wild
chimpanzees. J Virol 2007, 81:7463–7475.
24. Lee YN, Bieniasz PD: Reconstitution of an infectious human endogenous
retrovirus. PLoS Pathog 2007, 3:e10.
25. Wimmer E, Paul AV: Synthetic poliovirus and other designer viruses: what
have we learned from them? Annu Rev Microbiol 2011, 65:583–609.
26. Gibson DG, Smith HO, Hutchison CA 3rd, Venter JC, Merryman C: Chemical
synthesis of the mouse mitochondrial genome. Nat Methods 2010, 7:901–903.
27. Deom CM, He XZ, Beachy RN, Weissinger AK: Influence of heterologous
tobamovirus movement protein and chimeric-movement protein genes
on cell-to-cell and long-distance movement. Virology 1994, 205:198–209.
28. Fraenkel-Conrat H, Singer B: The stability of tobacco mosaic virus
ribonucleic acid. Bull Soc Chim Biol (Paris) 1958, 40:1717–1725.
29. Holt CA, Hodgson RA, Coker FA, Beachy RN, Nelson RS: Characterization of
the masked strain of tobacco mosaic virus: identification of the region
responsible for symptom attenuation by analysis of an infectious cDNA
clone. Mol Plant Microbe Interact 1990, 3:417–423.
30. Fraenkel-Conrat H, Singer B: Virus reconstitution. II. Combination of
protein and nucleic acid from different strains. Biochim Biophys Acta
1957, 24:540–548.31. Saito T, Meshi T, Takamatsu N, Okada Y: Coat protein gene sequence of
tobacco mosaic virus encodes a host response determinant. Proc Natl
Acad Sci U S A 1987, 84:6074–6077.
32. Culver JN, Dawson WO: Tobacco mosaic virus coat protein: an elicitor of
the hypersensitive reaction but not required for the development of
mosaic symptoms in Nicotiana sylvestris. Virology 1989, 173:755–758.
33. Sekine KT, Tomita R, Takeuchi S, Atsumi G, Saitoh H, Mizumoto H, Kiba A, Yamaoka
N, Nishiguchi M, Hikichi Y, Kobayashi K: Functional differentiation in the leucine-
rich repeat domains of closely related plant virus-resistance proteins that
recognize common avr proteins. Mol Plant Microbe Interact 2012, 25:1219–1229.
34. Knorr DA, Dawson WO: A point mutation in the tobacco mosaic virus
capsid protein gene induces hypersensitivity in Nicotiana sylvestris.
Proc Natl Acad Sci U S A 1988, 85:170–174.
35. Culver JN, Dawson WO: Point mutations in the coat protein gene of
tobacco mosaic virus induce hypersensitivity in Nicotiana sylvestris.
Mol Plant Microbe Interact 1989, 2:209–213.
36. Culver JN, Stubbs G, Dawson WO: Structure-function relationship between
tobacco mosaic virus coat protein and hypersensitivity in Nicotiana
sylvestris. J Mol Biol 1994, 242:130–138.
37. Taraporewala ZF, Culver JN: Identification of an elicitor active site within
the three-dimensional structure of the tobacco mosaic tobamovirus coat
protein. Plant Cell 1996, 8:169–178.
38. Hamilton RI, Dodds JA: Infection of barley by tobacco mosaic virus in
single and mixed infection. Virology 1970, 42:266–268.
39. Dodds JA, Hamilton RI: Masking of the RNA genome of tobacco mosaic
virus by the protein of barley stripe mosaic virus in doubly infected
barley. Virology 1974, 59:418–427.
40. Gibson DG, Glass JI, Lartigue C, Noskov VN, Chuang RY, Algire MA, Benders GA,
Montague MG, Ma L, Moodie MM, Merryman C, Vashee S, Krishnakumar R,
Assad-Garcia N, Andrews-Pfannkoch C, Denisova EA, Young L, Qi ZQ, Segall-
Shapiro TH, Calvey CH, Parmar PP, Hutchison CA 3rd, Smith HO, Venter JC:
Creation of a bacterial cell controlled by a chemically synthesized genome.
Science 2010, 329:52–56.
41. Hwang J, Oh CS, Kang BC: Translation elongation factor 1B (eEF1B) is
an essential host factor for Tobacco mosaic virus infection in plants.
Virology 2013, 439:105–114.
42. Yamaji Y, Kobayashi T, Hamada K, Sakurai K, Yoshii A, Suzuki M, Namba S,
Hibi T: In vivo interaction between Tobacco mosaic virus RNA-dependent
RNA polymerase and host translation elongation factor 1A. Virology 2006,
347:100–108.
43. Bhat S, Folimonova SY, Cole AB, Ballard KD, Lei Z, Watson BS, Sumner LW,
Nelson RS: Influence of host chloroplast proteins on Tobacco mosaic virus
accumulation and intercellular movement. Plant Physiol 2013, 161:134–147.
44. Osman TA, Buck KW: Identification of a region of the tobacco mosaic virus
126- and 183-kilodalton replication proteins which binds specifically to the
viral 3′-terminal tRNA-like structure. J Virol 2003, 77:8669–8675.
45. Jackson AO, Lim HS, Bragg J, Ganesan U, Lee MY: Hordeivirus replication,
movement, and pathogenesis. Annu Rev Phytopathol 2009, 47:385–422.
46. Guilley H, Jonard G, Kukla B, Richards KE: Sequence of 1000 nucleotides
at the 3′ end of tobacco mosaic virus RNA. Nucleic Acids Res 1979, 6:1287–1308.
47. Rouwendal GJ, Mendes O, Wolbert EJ, Douwe de Boer A: Enhanced
expression in tobacco of the gene encoding green fluorescent protein
by modification of its codon usage. Plant Mol Biol 1997, 33:989–999.
48. Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA 3rd, Smith HO:
Enzymatic assembly of DNA molecules up to several hundred kilobases.
Nat Methods 2009, 6:343–345.
49. Gooding GV Jr, Hebert TT: A simple technique for purification of tobacco
mosaic virus in large quantities. Phytopathology 1967, 57:1285.
50. Fraenkel-Conrat H: Degradation of tobacco mosaic virus with acetic acid.
Virology 1957, 4:1–4.
51. Ju C, Yoon GM, Shemansky JM, Lin D, Ying ZI, Chang J, Garrett W,
Kessenbrock M, Groth G, Tucker ML, Cooper B, Kieber JJ, Chang C: CTR1
phosphorylates the central regulator EIN2 to control ethylene hormone
signaling from the ER membrane to the nucleus in Arabidopsis. Proc Natl
Acad Sci U S A 2012, 109:19486–19491.
52. Tandem mass spectrometry data (RAW files). [http://dx.doi.org/10.6084/
m9.figshare.972912]
doi:10.1186/gb-2014-15-5-r67
Cite this article as: Cooper: Proof by synthesis of Tobacco mosaic virus.
Genome Biology 2014 15:R67.
